Literature DB >> 16222410

Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman-Sacks endocarditis: a case for antibiotic prophylaxis?

David Armstrong1, Stephen Wright, Claire McVeigh, Michael Finch.   

Abstract

We report a 54 year old female whose successful treatment of cerebral lupus with rituximab was complicated by the development of streptococcus intermedius, on valves damaged by Libman-Sacks endocarditis more than 20 years previously.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16222410     DOI： 10.1007/s10067-005-0031-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  11 in total

1.  Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.

Authors:  J S Li; D J Sexton; N Mick; R Nettles; V G Fowler; T Ryan; T Bashore; G R Corey
Journal:  Clin Infect Dis       Date:  2000-04-03       Impact factor: 9.079

2.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.

Authors:  J M Foran; A Z Rohatiner; D Cunningham; R A Popescu; P Solal-Celigny; M Ghielmini; B Coiffier; P W Johnson; C Gisselbrecht; F Reyes; J A Radford; E M Bessell; B Souleau; A Benzohra; T A Lister
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

3.  Prevalence of infective endocarditis in patients with systemic lupus erythematosus.

Authors:  C S Miller; R M Egan; D A Falace; M K Rayens; C R Moore
Journal:  J Am Dent Assoc       Date:  1999-03       Impact factor: 3.634

4.  An open study of B lymphocyte depletion in systemic lupus erythematosus.

Authors:  Maria J Leandro; Jonathan C Edwards; Geraldine Cambridge; Michael R Ehrenstein; David A Isenberg
Journal:  Arthritis Rheum       Date:  2002-10

5.  Cardiac abnormalities in SLE: pancarditis.

Authors:  M Bijl; J Brouwer; G G Kallenberg
Journal:  Lupus       Date:  2000       Impact factor: 2.911

6.  Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy.

Authors:  R Weide; J Heymanns; A Pandorf; H Köppler
Journal:  Lupus       Date:  2003       Impact factor: 2.911

7.  Endocarditis and Ureaplasma urealyticum osteomyelitis in a hypogammaglobulinemic patient. A case report and review of the literature.

Authors:  N G Frangogiannis; T R Cate
Journal:  J Infect       Date:  1998-09       Impact factor: 6.072

8.  Clinically significant valvular heart disease in systemic lupus erythematosus.

Authors:  K V Straaton; W W Chatham; J D Reveille; W J Koopman; S H Smith
Journal:  Am J Med       Date:  1988-11       Impact factor: 4.965

9.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

Authors:  Jonathan C W Edwards; Leszek Szczepanski; Jacek Szechinski; Anna Filipowicz-Sosnowska; Paul Emery; David R Close; Randall M Stevens; Tim Shaw
Journal:  N Engl J Med       Date:  2004-06-17       Impact factor: 91.245

10.  Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.

Authors:  Stefan Faderl; Deborah A Thomas; Susan O'Brien; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis J Giles; Charles Koller; Alessandra Ferrajoli; Srdan Verstovsek; Barbara Pro; Michael Andreeff; Miloslav Beran; Jorge Cortes; William Wierda; Ngoc Tran; Michael J Keating
Journal:  Blood       Date:  2003-01-09       Impact factor: 22.113
View more
  4 in total

Review 1.  Revisiting Libman-Sacks endocarditis: a historical review and update.

Authors:  Jennifer L Lee; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 2.  [Anti-B-cell strategies in vasculitides and collagenoses].

Authors:  A Rubbert-Roth
Journal:  Z Rheumatol       Date:  2009-07       Impact factor: 1.372

3.  Infective endocarditis in a patient with lupus nephritis who was undergoing immunosuppressive therapy: A case of survival.

Authors:  Katsuhito Ihara; Tatemitsu Rai; Shotaro Naito; Takayuki Toda; Sei Sasaki; Shinichi Uchida; Noriaki Matsui
Journal:  J Rural Med       Date:  2017-11-30

4.  Endocarditis following ocrelizumab in relapsing-remitting MS.

Authors:  Simon Faissner; Carolin Schwake; Michael Gotzmann; Andreas Mügge; Stephan Schmidt; Ralf Gold
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-02-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.